Related references
Note: Only part of the references are listed.Hospitalization Rates and Therapy Costs of German Schizophrenia Patients Who are Initiated on Long-Acting Injectable Medication: A Mirror-Image Study
Joerg Mahlich et al.
CLINICAL DRUG INVESTIGATION (2020)
Short-acting antipsychotics or long-acting injectables? A treatment comparison in patients with schizophrenia
Helena Thiem et al.
GESUNDHEITSOEKONOMIE UND QUALITAETSMANAGEMENT (2020)
Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: a systematic review and meta-analysis
Agumasie Semahegn et al.
SYSTEMATIC REVIEWS (2020)
Drug Survival of Biological Therapies for Psoriasis Treatment in Germany and Associated Costs: A Retrospective Claims Database Analysis
Joerg Mahlich et al.
ADVANCES IN THERAPY (2019)
Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder
Mallik Greene et al.
JOURNAL OF MEDICAL ECONOMICS (2018)
The impact of non-persistence on the direct and indirect costs in patients treated with subcutaneous tumour necrosis factor-alpha inhibitors in Germany
Kathrin Ziegelbauer et al.
RHEUMATOLOGY (2018)
Adherence and economic impact of paliperidone palmitate versus oral atypical antipsychotics in a Medicare population
Kruti Joshi et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2018)
Hepatocellular carcinoma after prior sorafenib treatment: incidence, healthcare utilisation and costs from German statutory health insurance claims data
Johannes Clouth et al.
HEALTH ECONOMICS REVIEW (2018)
Hospitalization rates and resource utilization of schizophrenic patients switched from oral antipsychotics to aripiprazole-depot in Germany
Christoph Potempa et al.
HEALTH ECONOMICS REVIEW (2018)
Productivity loss of caregivers of schizophrenia patients: a cross-sectional survey in Japan
Rosarin Sruamsiri et al.
JOURNAL OF MENTAL HEALTH (2018)
Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic
Dominic Pilon et al.
PATIENT PREFERENCE AND ADHERENCE (2017)
Non-adherence to pharmacological treatment in schizophrenia and schizophrenia spectrum disorders - An updated systematic literature review
P. M. Ljungdalh
EUROPEAN JOURNAL OF PSYCHIATRY (2017)
Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics
Dominic Pilon et al.
CLINICAL THERAPEUTICS (2017)
Drug Utilization of Japanese Patients Diagnosed with Schizophrenia: An Administrative Database Analysis
Stephane Cheung et al.
CLINICAL DRUG INVESTIGATION (2017)
Risk of discontinuation of antipsychotic long-acting injections vs. oral antipsychotics in real-life prescribing practice: a community-based study
H. Verdoux et al.
ACTA PSYCHIATRICA SCANDINAVICA (2017)
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence
Christoph U. Correll et al.
JOURNAL OF CLINICAL PSYCHIATRY (2016)
Persistence with biologic agents for the treatment of rheumatoid arthritis in Japan
Joerg Mahlich et al.
PATIENT PREFERENCE AND ADHERENCE (2016)
Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan
Jorg Mahlich et al.
CLINICOECONOMICS AND OUTCOMES RESEARCH (2015)
The economic burden of schizophrenia in Germany: A population-based retrospective cohort study using genetic matching
S. Frey
EUROPEAN PSYCHIATRY (2014)
Medication Adherence and Hospitalization Among Patients With Schizophrenia Treated With Antipsychotics
Kathleen Lang et al.
PSYCHIATRIC SERVICES (2014)
Healthcare Cost Reductions Associated with the Use of LAI Formulations of Antipsychotic Medications Versus Oral Among Patients with Schizophrenia
Jay Lin et al.
JOURNAL OF BEHAVIORAL HEALTH SERVICES & RESEARCH (2013)
The Cost Effectiveness of Long-Acting/Extended-Release Antipsychotics for the Treatment of Schizophrenia A Systematic Review of Economic Evaluations
Evanthia Achilla et al.
APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2013)
Cost Effectiveness of Paliperidone Palmitate for the Treatment of Schizophrenia in Germany
Jan Zeidler et al.
APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2013)
Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review
Kyoko Higashi et al.
THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY (2013)
Cognitive Impairment Associated with Schizophrenia: a Review of the Humanistic Burden
Helen Kitchen et al.
ADVANCES IN THERAPY (2012)
Cognitive deficits in schizophrenia: an updated metanalysis of the scientific evidence
Mario Fioravanti et al.
BMC PSYCHIATRY (2012)
Interventions to improve adherence to antipsychotic medication in patients with schizophrenia-A review of the past decade
E. Barkhof et al.
EUROPEAN PSYCHIATRY (2012)
Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS)
Lamiae Grimaldi-Bensouda et al.
SCHIZOPHRENIA RESEARCH (2012)
A Nationwide Cohort Study of Oral and Depot Antipsychotics After First Hospitalization for Schizophrenia
Jari Tiihonen et al.
AMERICAN JOURNAL OF PSYCHIATRY (2011)
The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden
Michael Willis et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2010)
Partial compliance with antipsychotic medication is common in patients with schizophrenia
Christine Rummel-Kluge et al.
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY (2008)
Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia
Gunnar Morken et al.
BMC PSYCHIATRY (2008)
Off-label use of antipsychotics: are we mad?
Camilla Haw et al.
EXPERT OPINION ON DRUG SAFETY (2007)
Failure of ICD-9-CM codes to identify patients with comorbid chronic kidney disease in diabetes
EFO Kern et al.
HEALTH SERVICES RESEARCH (2006)
Assessment of compliance with antipsychotic treatment and resource utilization in a medicaid population
M Eaddy et al.
CLINICAL THERAPEUTICS (2005)
Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany
G Laux et al.
PHARMACOECONOMICS (2005)
Adherence to treatment with antipsychotic medication and health care costs among medicaid beneficiaries with schizophrenia
TP Gilmer et al.
AMERICAN JOURNAL OF PSYCHIATRY (2004)
Variations in patients' adherence to medical recommendations - A quantitative review of 50 years of research
MR DiMatteo
MEDICAL CARE (2004)
Non-adherence to antipsychotic medication regimens: associations with resource use and costs
M Knapp et al.
BRITISH JOURNAL OF PSYCHIATRY (2004)
Share Paper
